TY - JOUR
T1 - Lipid-lowering agents use and systemic and oral inflammation in overweight or obese adult Puerto Ricans
T2 - The San Juan Overweight Adults Longitudinal Study (SOALS)
AU - Andriankaja, Oelisoa M.
AU - Jiménez, James J.
AU - Muñoz-Torres, Francisco J.
AU - Pérez, Cynthia M.
AU - Vergara, José L.
AU - Joshipura, Kaumudi J.
N1 - Publisher Copyright:
© 2015 John Wiley & Sons A/S.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - The effects of lipid-lowering agents (LLA) on reducing systemic and oral inflammation have not been evaluated. Objective To assess the association of LLA use with high-sensitivity C-reactive protein (hs-CRP) and oral inflammation. Design Cross-sectional analysis using baseline data from 1300 overweight/obese participants aged 40-65 years, recruited for the ongoing San Juan Overweight Adults Longitudinal Study. Serum hs-CRP was measured by ELISA, gingival/periodontal inflammation was evaluated as bleeding upon probing (BOP), and LLA was self-reported. Separate logistic models were performed for systemic and oral inflammation. Results In all, 24% participants reported history of dyslipidaemia, of which, 50.3% self-reported LLA use. Sixty percent of the participants had elevated hs-CRP (>3 mg/dl) and 50% had high BOP (defined as at or above the median: 21%). After adjusting for age, gender, smoking, HDL-C, physical activity, diabetes, blood pressure medications, and percent body fat composition, LLA users had significantly lower odds of elevated hs-CRP compared to LLA non-users (OR = 0.58; 95% CI: 0.39-0.85). After adjusting for age, gender, smoking status, educational level, mean plaque index and percent body fat, LLA users had significantly lower odds of high BOP compared to LLA non-users (OR = 0.62; 95% CI: 0.42-0.91). Conclusions Lipid-lowering agents may reduce both systemic and oral inflammatory responses.
AB - The effects of lipid-lowering agents (LLA) on reducing systemic and oral inflammation have not been evaluated. Objective To assess the association of LLA use with high-sensitivity C-reactive protein (hs-CRP) and oral inflammation. Design Cross-sectional analysis using baseline data from 1300 overweight/obese participants aged 40-65 years, recruited for the ongoing San Juan Overweight Adults Longitudinal Study. Serum hs-CRP was measured by ELISA, gingival/periodontal inflammation was evaluated as bleeding upon probing (BOP), and LLA was self-reported. Separate logistic models were performed for systemic and oral inflammation. Results In all, 24% participants reported history of dyslipidaemia, of which, 50.3% self-reported LLA use. Sixty percent of the participants had elevated hs-CRP (>3 mg/dl) and 50% had high BOP (defined as at or above the median: 21%). After adjusting for age, gender, smoking, HDL-C, physical activity, diabetes, blood pressure medications, and percent body fat composition, LLA users had significantly lower odds of elevated hs-CRP compared to LLA non-users (OR = 0.58; 95% CI: 0.39-0.85). After adjusting for age, gender, smoking status, educational level, mean plaque index and percent body fat, LLA users had significantly lower odds of high BOP compared to LLA non-users (OR = 0.62; 95% CI: 0.42-0.91). Conclusions Lipid-lowering agents may reduce both systemic and oral inflammatory responses.
KW - hs-CRP
KW - lipid-lowering agents
KW - periodontitis
KW - statins
KW - systemic inflammation
UR - http://www.scopus.com/inward/record.url?scp=84955196242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955196242&partnerID=8YFLogxK
U2 - 10.1111/jcpe.12461
DO - 10.1111/jcpe.12461
M3 - Article
C2 - 26407668
AN - SCOPUS:84955196242
SN - 0303-6979
VL - 42
SP - 1090
EP - 1096
JO - Journal of Clinical Periodontology
JF - Journal of Clinical Periodontology
IS - 12
ER -